FI964862L - FLT4-reseptorityrosiinikinaasi ja sen käyttö diagnostiikassa ja terapiassa - Google Patents

FLT4-reseptorityrosiinikinaasi ja sen käyttö diagnostiikassa ja terapiassa Download PDF

Info

Publication number
FI964862L
FI964862L FI964862A FI964862A FI964862L FI 964862 L FI964862 L FI 964862L FI 964862 A FI964862 A FI 964862A FI 964862 A FI964862 A FI 964862A FI 964862 L FI964862 L FI 964862L
Authority
FI
Finland
Prior art keywords
diagnostics
therapy
tyrosine kinase
receptor tyrosine
flt4 receptor
Prior art date
Application number
FI964862A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI964862A7 (fi
FI964862A0 (fi
Inventor
Kari Alitalo
Arja Kaipainen
Jaana Korhonen
Tuija Mustonen
Katri Pajusola
Marja-Terttu Matikainen
Paeivi Karnani
Original Assignee
Kari Alitalo
Arja Kaipainen
Jaana Korhonen
Tuija Mustonen
Katri Pajusola
Matikainen Marja Terttu
Paeivi Karnani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kari Alitalo, Arja Kaipainen, Jaana Korhonen, Tuija Mustonen, Katri Pajusola, Matikainen Marja Terttu, Paeivi Karnani filed Critical Kari Alitalo
Priority to FI964862A priority Critical patent/FI964862L/fi
Publication of FI964862A0 publication Critical patent/FI964862A0/fi
Publication of FI964862A7 publication Critical patent/FI964862A7/fi
Publication of FI964862L publication Critical patent/FI964862L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI964862A 1994-06-09 1995-06-09 FLT4-reseptorityrosiinikinaasi ja sen käyttö diagnostiikassa ja terapiassa FI964862L (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI964862A FI964862L (fi) 1994-06-09 1995-06-09 FLT4-reseptorityrosiinikinaasi ja sen käyttö diagnostiikassa ja terapiassa

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25775494A 1994-06-09 1994-06-09
PCT/FI1995/000337 WO1995033772A1 (en) 1994-06-09 1995-06-09 Flt4 receptor tyrosine kinase and its use in diagnosis and therapy
FI964862A FI964862L (fi) 1994-06-09 1995-06-09 FLT4-reseptorityrosiinikinaasi ja sen käyttö diagnostiikassa ja terapiassa

Publications (3)

Publication Number Publication Date
FI964862A0 FI964862A0 (fi) 1996-12-04
FI964862A7 FI964862A7 (fi) 1997-02-10
FI964862L true FI964862L (fi) 1997-02-10

Family

ID=22977612

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964862A FI964862L (fi) 1994-06-09 1995-06-09 FLT4-reseptorityrosiinikinaasi ja sen käyttö diagnostiikassa ja terapiassa

Country Status (14)

Country Link
EP (1) EP0807124B1 (da)
JP (4) JP3723210B2 (da)
AT (1) ATE326484T1 (da)
AU (1) AU694524B2 (da)
CA (1) CA2192235C (da)
DE (1) DE69534996T2 (da)
DK (1) DK0807124T3 (da)
ES (1) ES2263152T3 (da)
FI (1) FI964862L (da)
MX (1) MX9606218A (da)
NO (1) NO319383B1 (da)
NZ (1) NZ288235A (da)
PT (1) PT807124E (da)
WO (1) WO1995033772A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
EP1353952B1 (en) 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
ATE242809T1 (de) 1995-09-08 2003-06-15 Genentech Inc Vegf-verwandtes protein
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
FR2783325A1 (fr) * 1998-09-11 2000-03-17 Inst Nat Sante Rech Med Moyens pour le controle de la regulation negative d'une activation transmise par un rtk
NZ529063A (en) 1998-10-09 2005-07-29 Ludwig Inst Cancer Res Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
AU775583B2 (en) * 1999-04-13 2004-08-05 Medarex, Inc. Methods for the diagnosis and treatment of metastatic prostate tumors
EP1553414A1 (en) * 1999-04-13 2005-07-13 Medarex, Inc. Methods for the diagnosis and treatment of metastatic prostate tumors
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US6599717B1 (en) * 1999-10-01 2003-07-29 Exelixis, Inc. Invertebrate vascular endothelial growth factor receptor
EP2025686A4 (en) * 2006-05-29 2009-12-23 Consejo Superior Investigacion MONOCLONAL ALPHA ANTICHOLIN KINASE ANTIBODIES AND ITS USE IN ANALYTICAL METHODS FOR THE DIAGNOSIS OF CANCER AND FOR THE MANUFACTURE OF MEDICINE PRODUCTS
EP2125895B1 (en) 2007-02-02 2015-04-08 Vegenics Pty Ltd Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis
MX368730B (es) 2013-02-18 2019-10-14 Vegenics Pty Ltd Moleculas que unen ligando y usos de las mismas.
EP2994758B1 (en) 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940703857A (ko) * 1992-01-09 1994-12-12 티모 에스코 타이, 새로운 내피 세포 수용체 티로신 키나제(tie, a novel endothelial cell receptor tyrosine kinase)
CZ291047B6 (cs) * 1992-10-28 2002-12-11 Genentech, Inc. Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk

Also Published As

Publication number Publication date
CA2192235A1 (en) 1995-12-14
NZ288235A (en) 1999-05-28
DE69534996D1 (de) 2006-06-22
FI964862A7 (fi) 1997-02-10
AU694524B2 (en) 1998-07-23
JP2009102415A (ja) 2009-05-14
JP3723210B2 (ja) 2005-12-07
MX9606218A (es) 1998-02-28
JP2005139199A (ja) 2005-06-02
DK0807124T3 (da) 2006-08-28
EP0807124A1 (en) 1997-11-19
NO965231D0 (no) 1996-12-06
CA2192235C (en) 2011-02-15
FI964862A0 (fi) 1996-12-04
AU2738895A (en) 1996-01-04
NO319383B1 (no) 2005-07-25
DE69534996T2 (de) 2007-05-10
ATE326484T1 (de) 2006-06-15
PT807124E (pt) 2006-08-31
EP0807124B1 (en) 2006-05-17
ES2263152T3 (es) 2006-12-01
JPH10500858A (ja) 1998-01-27
WO1995033772A1 (en) 1995-12-14
JP2012193191A (ja) 2012-10-11
NO965231L (no) 1996-12-06

Similar Documents

Publication Publication Date Title
FI964862L (fi) FLT4-reseptorityrosiinikinaasi ja sen käyttö diagnostiikassa ja terapiassa
DK0877734T3 (da) Quinolin- og quinazolinforbindelser, der er egnede i terapi
EE9700209A (et) Dihüdropürimidiinid ja nende kasutamine
FI960888A7 (fi) Protokadheriiniproteiineja ja niiden käyttö
NO934163D0 (no) HER4 human reseptor-tyrosinkinase
FI963126L (fi) Stanoliseos ja sen käyttö
FI946005L (fi) Glysiinireseptoriantagonisteja ja niiden käyttö
EE03482B1 (et) Kinasoliiniderivaadid, nende valmistamismeetod ja kasutamine
EE9700039A (et) Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess
FI955235L (fi) Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
FI934220A7 (fi) Piperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
FI964334A7 (fi) Polymeroitava koostumus ja sen käyttö
FI953479A7 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
FI944600A0 (fi) Imidatsol-4-yylipiperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
EE9600172A (et) Puriin-6-ooni derivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja ravimid
DE69230654D1 (de) Commiphora-Mukul-Extrakte und deren therapeutische Verwendung
EE9700288A (et) Asatsükloalkaani derivaadid, nende valmistamine ja kasutamine ravis
NZ328371A (en) Method of detecting a ligand capable of binding the receptor protein neuroepithelial tyrosine kinase (nyk) and its use in therapeutic compositions
BR9608896A (pt) Derivados de oxazolidinona sua preparação e uso terapêutico
FI940425A7 (fi) Modifioidut oligodeoksiribonukleotidit, niiden valmistus ja niiden terapeuttinen käyttö
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
EE9900135A (et) N-(2-bensotiasolüül)-1-piperidiinetaanamiini derivaadid, nende valmistamine ja kasutamine raviks
FI954141L (fi) Oksatsolokinolonijohdannaiset, niiden valmistus ja niiden käyttö terapiassa
FI935196A7 (fi) Pyrrolijohdannaisia, niiden valmistus ja käyttö terapiassa
FI971528A7 (fi) Pyrrolyylitetrahydrobentsokinoksaliinidionit, niiden valmistus ja käyt tö glutamaattireseptoriantagonisteina

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: HELSINKI UNIVERSITY LICENSING LTD OY

PC Transfer of assignment of patent

Owner name: ORION-YHTYMAE OYJ

Free format text: ORION-YHTYMAE OYJ

Owner name: LICENTIA OY

Free format text: LICENTIA OY